Cholangiocarcinoma

This case raises the possibility of an association between Maffucci syndrome and recurrent papillary breast lesions. In the absence of molecular confirmation, this relationship remains speculative and should be regarded as hypothesis generating, underscoring the need for further investigation with genetic and immunohistochemical correlation rather than changes to established breast cancer screening guidelines.

KMT2A was significantly upregulated in intrahepatic cholangiocarcinoma and elevated H3K4me3 levels at the JAK2 promoter, leading to higher JAK2 expression and activation of the JAK2/STAT3 pathway, which, in turn, stimulated ICC cell proliferation. This study offers novel insights into the potential of KMT2A as both a prognostic biomarker and therapeutic target for intrahepatic cholangiocarcinoma.

They received eight cycles of gemcitabine, cisplatin, and durvalumab, followed by durvalumab monotherapy (five and six cycles, respectively) for a total of approximately 11 months. Corticosteroids remain the cornerstone of treatment, and high-dose pulse therapy may be necessary in refractory cases. In conclusion, recognition of durvalumab-induced ES is crucial for appropriate management.

Progression-free survival was 12.8 months and overall survival reached 44.4 months. This case underscores the importance of early molecular profiling and supports the integration of targeted therapies into routine clinical practice for tumors with limited effective therapeutic options.

Our results reveal a critical role for the IGF2BP1-HMGA2 axis in iCCA pathogenesis, thereby highlighting its potential as a therapeutic target.

P=N/A, N=3000, Completed, Centre Hospitalier Universitaire, Amiens | Unknown status --> Completed

P2, N=92, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting

The EHBH-HCCA staging system provides enhanced prognostic stratification for HCCA patients following surgical resection. This novel approach offers potential for improved clinical decision-making and personalized treatment regimen.

Additionally, combination of Bru with Cis or Gem significantly reduced colony formation, and suppressed cell migration and invasion in KKU-100 cells. These findings support the potential of Bru as a promising anti-cancer agent or adjunct therapy to enhance current chemotherapy in CCA treatment.

P=N/A, N=170, Recruiting, Insel Gruppe AG, University Hospital Bern | Trial completion date: Jul 2029 --> Oct 2030 | Trial primary completion date: Jul 2029 --> Oct 2030

P2, N=58, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Sep 2026 | Trial primary completion date: Mar 2025 --> Sep 2026

P1/2, N=260, Terminated, Amgen | Completed --> Terminated; Sponsor Decision